Legislative update : The mixed bag of Medicare drug coverage by Charles Gerena
T
he Medicare reform bill signed by President Bush last
December will help thousands of Medicare recipients
by providing drug coverage for the first time. But it
comes at a high price in terms of its potential macroeconomic
consequences and unintended effects on access to drugs.
Starting in 2006, seniors can choose a stand-alone prescription
drug plan (PDP) under Medicare Part D or drug coverage
through a Medicare Advantage comprehensive plan (formerly
Medicare+Choice or Part C). The standard drug benefit will
cover 75 percent of medication costs between $250 and $2,250,
then no further assistance will be provided until expenses reach
a “catastrophic” level of $5,100. Those
with low incomes may qualify for a special
drug benefit with no gap in coverage.
Drug coverage will add approximately
$534 billion to the cost of Medicare over
10 years. Such a large expansion in an
entitlement program carries the risk of
pushing the federal budget into structural
imbalance, whereby planned government
expenses exceed average tax revenues
generated by an expected level of
economic activity. Entitlements, which
already consume more than half of the
budget, are much harder to cut than
discretionary programs.
What will stop mounting drug prices
from ballooning the overall cost of
Medicare? Congress hopes the drug
benefit will save money by encouraging
more seniors to use medications that prevent conditions before
they worsen and require expensive treatment. Generally, seniors
with insurance are less price sensitive in their demand for drugs.
“They don’t think very much about the cost,” says Roland
McDevitt, a senior consultant for Watson Wyatt Worldwide.
“They take whatever [the doctor] prescribes and get the latest
generation of drugs designed for their condition.”
To keep the fiscal burden of the Medicare drug benefit from
growing out of control, lawmakers put cost-containment
mechanisms into place. For example, as Medicare Part D
spending rises, the deductible and the level at which catastrophic
coverage starts will rise as well. This will shift more costs onto
Medicare beneficiaries. 
Will cost shifting help contain overall drug prices as well? Lynn
Taylor, senior policy analyst at the Institute for Health Policy
Solutions, says the coverage gap will result in the most financial
assistance going to occasional users of drugs and frequent users,
leaving the average Medicare recipient to pay for their medications
out of pocket. “Any time you make people absorb more of the
costs, the theory is that it will make them more conservative
about what they purchase,” explains Taylor. “But to put [a gap]
in the middle as opposed to having a high up-front deductible
or higher cost sharing, I don’t know what the rationale is for that.”
Most observers believe the coverage gap kept the price tag of
Medicare drug coverage at a politically acceptable level. 
Another way that lawmakers hope to rein in costs is to bring
private-sector competition into the delivery of drug coverage.
The federal Centers for Medicare and Medicaid Services will
contract with health insurers to provide PDPs and Medicare
Advantage plans with drug benefits. The country will be divided
into at least 10 regions, and a minimum
of two drug plans from different firms
will have to be available in each region.
These insurers are expected to
negotiate lower prices for drugs, but
policy analysts like Edwin Park of the
Center on Budget and Policy Priorities
have their doubts. Park says the best
way for them to secure a discount is to
guarantee a certain market share for a
drug manufacturer, usually by adding its
product to their preferred drug list. But
he questions whether this would be
achievable. “How much market share
are you delivering when you are breaking
up [the market] into multiple regions?”
Furthermore, Park thinks it’s unlikely
that firms could get better drug bargains
than large government purchasers like
the Veterans Administration could.
Private insurers also are expected to use cost- containment
tools more aggressively than government agencies could. They
won’t be subject to political pressures, plus they will be able to
use preferred drug lists. 
The downside of using such tactics is that some drugs may
not be covered or may require a higher co-payment. This won’t
be an issue if seniors can shop around for drug coverage that includes
their medications. Additional payments will be given to health
insurers to offer PHPs and Medicare Advantage plans, but
Families USA, a healthcare advocacy group, notes that some
regions may not get any takers. 
All told, seniors will have fewer alternatives if no Medicare-
sponsored plan works for them. Medicaid won’t be allowed to
fill in coverage gaps in the Medicare drug program, while states
would be hard-pressed to fill the gaps on their own. Furthermore,
employers could eliminate drug coverage for retirees when the




The Mixed Bag of Medicare Drug Coverage
Basic Medicare Drug Benefit
Plan Component Beneficiaries Pay
Premium $35/month ($420/year)
Deductible $250
Initial coverage 25 percent of expenses
between $250 and
$2,250
Coverage gap All expenses between
$2,250 and $5,100
Catastrophic 5 percent of expenses
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